Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure
Phase 3negativeNegative
AI Analysis
Summary
Theravance is shutting down its R&D operations and cutting workforce by half following a Phase III trial failure. The company will transition to generating revenue from two partnered, commercialized assets.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Phase III trial failure
Importance:8/10
Sentiment:
-0.90
R&D shutdownworkforce reductiontrial failurerestructuring
Read the original article
Published by Clinical Trials Arena on March 4, 2026 11:32 AM